Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension

A recent study demonstrated a significant role for leukotriene B4 (LTB4) causing pulmonary vascular remodeling in pulmonary arterial hypertension. LTB4 was found to directly injure luminal endothelial cells and promote growth of the smooth muscle cell layer of pulmonary arterioles. The purpose of this study was to determine the effects of LTB4 on the pulmonary adventitial layer, largely composed of fibroblasts. Here, we demonstrate that LTB4 enhanced human pulmonary artery adventitial fibroblast proliferation, migration, and differentiation in a dose-dependent manner through its cognate G-protein–coupled receptor, BLT1. LTB4 activated human pulmonary artery adventitial fibroblast by upregulating p38 mitogen-activated protein kinase as well as Nox4-signaling pathways. In an autoimmune model of pulmonary hypertension, inhibition of these pathways blocked perivascular inflammation, decreased Nox4 expression, reduced reactive oxygen species production, reversed arteriolar adventitial fibroblast activation, and attenuated pulmonary hypertension development. This study uncovers a novel mechanism by which LTB4 further promotes pulmonary arterial hypertension pathogenesis, beyond its established effects on endothelial and smooth muscle cells, by activating adventitial fibroblasts.

[1]  M. Humbert,et al.  New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. , 2015, Chest.

[2]  E. Nozik-Grayck,et al.  Role of reactive oxygen species in chronic hypoxia-induced pulmonary hypertension and vascular remodeling. , 2007, Advances in experimental medicine and biology.

[3]  T. McKinsey,et al.  Emergence of Fibroblasts with a Proinflammatory Epigenetically Altered Phenotype in Severe Hypoxic Pulmonary Hypertension , 2011, The Journal of Immunology.

[4]  E. Nozik-Grayck,et al.  The adventitia: essential regulator of vascular wall structure and function. , 2013, Annual review of physiology.

[5]  Yin Xiao,et al.  Inhibition of p38 pathway leads to OA-like changes in a rat animal model. , 2012, Rheumatology.

[6]  K. Krause,et al.  Reactive oxygen species: from health to disease. , 2012, Swiss medical weekly.

[7]  E. Spiekerkoetter,et al.  Current clinical management of pulmonary arterial hypertension. , 2014, Circulation research.

[8]  M. Humbert,et al.  Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension , 2014, Circulation.

[9]  T. Yue,et al.  Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. , 1999, Circulation.

[10]  Keisuke Ito,et al.  Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells , 2006, Nature Medicine.

[11]  S. Sankey,et al.  Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. , 2005, Journal of cardiac failure.

[12]  A. Anwar,et al.  Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[13]  W. Busse,et al.  The Effect of Inhibition of 5-Lipoxygenase by Zileuton in Mild-to-Moderate Asthma , 1993, Annals of Internal Medicine.

[14]  S. Barman,et al.  From form to function: the role of Nox4 in the cardiovascular system , 2012, Front. Physio..

[15]  K. Griendling,et al.  Nox proteins in signal transduction. , 2009, Free radical biology & medicine.

[16]  Y. Yun,et al.  Sustained expression of NADPH oxidase 4 by p38 MAPK-Akt signaling potentiates radiation-induced differentiation of lung fibroblasts , 2010, Journal of Molecular Medicine.

[17]  Yunchao Su,et al.  NADPH Oxidase 4 Is Expressed in Pulmonary Artery Adventitia and Contributes to Hypertensive Vascular Remodeling , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[18]  D. Welsh,et al.  The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension , 2015, American journal of physiology. Lung cellular and molecular physiology.

[19]  S. Pullamsetti,et al.  Adventitial Fibroblasts Induce a Distinct Proinflammatory/Profibrotic Macrophage Phenotype in Pulmonary Hypertension , 2014, The Journal of Immunology.

[20]  J. S. Muhammad,et al.  Pulmonary Hypertension in Systemic Sclerosis , 2011 .

[21]  C. Long,et al.  Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary Hypertension , 2011, Circulation research.

[22]  S. Black,et al.  Reactive oxygen species in pulmonary vascular remodeling. , 2013, Comprehensive Physiology.

[23]  M. Frid,et al.  Hypoxia-induced Pulmonary Vascular Remodeling Cellular and Molecular Mechanisms Reviews , 2022 .

[24]  E. Mark,et al.  Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.

[25]  A. Anwar,et al.  The adventitia: Essential role in pulmonary vascular remodeling. , 2010, Comprehensive Physiology.

[26]  P. ten Dijke,et al.  Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. , 2008, Arthritis and rheumatism.

[27]  A. Della Corte,et al.  Role of myofibroblasts in vascular remodelling: focus on restenosis and aneurysm. , 2010, Cardiovascular research.

[28]  K. Stenmark,et al.  Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGFβ receptor-JNK1 signalling. , 2012, Cardiovascular research.

[29]  T. McKinsey,et al.  Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change , 2012, Pulmonary circulation.

[30]  T. Cohnert,et al.  Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Welsh,et al.  Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. , 2009, American journal of physiology. Heart and circulatory physiology.

[32]  M. Peters-Golden,et al.  5-lipoxygenase and FLAP. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[33]  Jiahuai Han,et al.  Activation and signaling of the p38 MAP kinase pathway , 2005, Cell Research.

[34]  Jae-Hong Kim,et al.  Bioactive lipoxygenase metabolites stimulation of NADPH oxidases and reactive oxygen species , 2011, Molecules and cells.

[35]  Manesh R. Patel,et al.  Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial , 2014, The Lancet.

[36]  J. Molkentin,et al.  Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion. , 2005, American journal of physiology. Heart and circulatory physiology.

[37]  O. Werz,et al.  5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Schnittler,et al.  Nox4 overexpression activates reactive oxygen species and p38 MAPK in human endothelial cells. , 2009, Biochemical and biophysical research communications.

[39]  T. Ochiya,et al.  Silencing of S100A4, a metastasis-associated protein, in endothelial cells inhibits tumor angiogenesis and growth , 2013, Angiogenesis.

[40]  John C. Lee,et al.  Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. , 1999, Biochemical and biophysical research communications.

[41]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[42]  K. Krause,et al.  The NADPH oxidase NOX4 drives cardiac differentiation: Role in regulating cardiac transcription factors and MAP kinase activation. , 2006, Molecular biology of the cell.

[43]  D. Welsh,et al.  Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. , 2001, American journal of respiratory and critical care medicine.

[44]  M. Humbert,et al.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. , 2014, Circulation research.

[45]  Duo Wei,et al.  p38 mitogen-activated protein kinase inhibition attenuates burn-induced liver injury in rats. , 2005, Burns : journal of the International Society for Burn Injuries.

[46]  W. Roberts,et al.  Molecular characterization of reactive oxygen species in systemic and pulmonary hypertension. , 2014, American journal of hypertension.

[47]  L. Chung,et al.  Epidemiology and Risk Factors for Pulmonary Hypertension in Systemic Sclerosis , 2012, Current Rheumatology Reports.

[48]  R. Tuder,et al.  Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.

[49]  I. Wilkinson,et al.  Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease , 2014, American Journal of Cardiovascular Drugs.

[50]  B. Samuelsson,et al.  Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. , 2010, Biochemical and biophysical research communications.

[51]  Daphne Merkus,et al.  Reactive Oxygen Species and the Cardiovascular System , 2013, Oxidative medicine and cellular longevity.

[52]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[53]  L. Howard,et al.  Connective tissue disease-associated pulmonary arterial hypertension , 2015, F1000prime reports.

[54]  D. Welsh,et al.  p38 MAP kinase isoform activity and cell cycle regulators in the proliferative response of pulmonary and systemic artery fibroblasts to acute hypoxia. , 2006, Pulmonary pharmacology & therapeutics.

[55]  T. Hirano,et al.  IL-6 in autoimmune disease and chronic inflammatory proliferative disease. , 2002, Cytokine & growth factor reviews.

[56]  M. A. Moseley,et al.  Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S-nitrosylation. , 2012, Free radical biology & medicine.

[57]  E. K. Weir,et al.  Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.

[58]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[59]  K. Stenmark,et al.  Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia. , 2008, Cardiovascular research.

[60]  D. Welsh,et al.  Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. , 2007, American journal of respiratory cell and molecular biology.

[61]  M. Peters-Golden,et al.  Nuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[62]  L. Farkas,et al.  Blocking Macrophage Leukotriene B4 Prevents Endothelial Injury and Reverses Pulmonary Hypertension , 2013, Science Translational Medicine.

[63]  M. Gladwin,et al.  Pulmonary arterial hypertension: the clinical syndrome. , 2014, Circulation research.

[64]  Sanjiv J. Shah,et al.  Management of Pulmonary Arterial Hypertension , 2015, Seminars in Respiratory and Critical Care Medicine.

[65]  J. Gulcher,et al.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke , 2004, Nature Genetics.

[66]  M. Frid,et al.  Role of the adventitia in pulmonary vascular remodeling. , 2006, Physiology.